SEC filing record
Primary Source · SEC.gov

Talos Biotech

Single-Deal SPV2026 vintage506(b)
Latest signalNew Form D filerForm D · 2026-11-19Last filing 2026-11-19

Raised

$185K

Investors

4

Min Invest

$25,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

Talos Biotech is a Wyoming-incorporated entity that filed a Form D on 2026-11-19 for a 506(b) exempt offering, reporting $185K raised from 4 investors at a $25K minimum investment. The filing lists William Short (Executive Officer, Director, Promoter) and Daniel Finley (Executive Officer) as related persons, with the first sale date not disclosed. No parent platform or related sibling entities were identified in available data.

This is a small-scale 506(b) private placement typical of early-stage alternative investment vehicles, with a $25K minimum investment and a modest $185K raise across 4 investors — well below typical institutional fund sizes in this category. The 506(b) exemption (versus 506(c)) suggests the offering was not publicly solicited, consistent with a closely-held early-stage raise.

Data Flags

Securities TypeSecurities type is listed as 'Other' rather than a standard equity/debt/pooled fund interest classification, which is unusual and limits clarity on the investment structure.
First Sale DateFirst sale date is not disclosed despite the raise being under $100M, which would normally be expected on a standard Form D filing.
Industry GroupIndustry group is not specified despite the entity name ('Biotech') suggesting a life sciences focus.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002156374
Entity NameTalos Biotech
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationWyoming
Year Organized2026
Issuer Address6224 W Seltice Way, Unit 109, Post Falls, ID 83854
Phone(208) 640-7572
Industry / Fund TypeManufacturing
Securities TypeOther
First Sale Date—
Filing DateNovember 19, 2026
Accession Number0002156374-26-000001
Total Offering Amount$300,000
Total Amount Sold$185,000
Amount Remaining$115,000
Total Investors4
Non-Accredited InvestorsNone
Minimum Investment$25,000
Offering DurationOne year or less
Sales Commissions$0
Finders' Fees$0
Proceeds to Related Persons$0
Revenue RangeNo Revenues
State (Issuer Address)ID
Amendment CountOriginal filing only
Signed ByDaniel W Finley, Chief Operations Officer

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Nov 19, 2026

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event New filer · Nov 19, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2026-11-19, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

William Short

Executive Officer, Director, Promoter · Post Falls, ID

Daniel Finley

Executive Officer · Post Falls, ID

Questions About Talos Biotech

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Talos Biotech?

Talos Biotech is a Wyoming corporation organized in 2026 that filed a Form D with the SEC on November 19, 2026 in the Manufacturing industry group. The filing claims Rule 506(b).

Is Talos Biotech legit?

AltStreet does not rate legitimacy; it reports the public record. Talos Biotech filed a Form D with the SEC on November 19, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $185,000 sold to 4 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Talos Biotech registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Talos Biotech claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Talos Biotech raised?

Talos Biotech reported $185,000 sold from 4 investors of a $300,000 total offering as of the Form D filed November 19, 2026.

Who can invest in Talos Biotech?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $25,000.

What is the minimum investment in Talos Biotech?

The Form D lists $25,000 as the minimum investment accepted from any outside investor as of November 19, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Talos Biotech and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Talos Biotech?

The Form D lists 2 related persons: William Short, executive officer, director, promoter; Daniel William Finley, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Talos Biotech located?

The issuer's address on its SEC filings is 6224 W Seltice Way, Unit 109, Post Falls, ID 83854. Its phone number of record is 208 640 7572. It is organized under the laws of Wyoming.

How long is the Talos Biotech offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Talos Biotech's revenue?

The Form D reports a revenue range of No Revenues.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.